EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework

Sharonjit K Dhillon, Clementina E Cocuzza iD, Pui Yan Jenny Chung, Marianna Martinelli, Chiara Giubbi, Ruth C Njoku, Ramya Bhatia iD, Kate Cuschieri, Marc Arbyn

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Sharonjit K Dhillon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus (HPV) assays used in cervical cancer screening should be clinically validated according to international criteria. OncoPredict HPV® Screening (SCR) is a partial genotyping multiplex real‐time PCR assay targeting E6/E7 genes of 13 high‐risk (hr) HPVs. OncoPredict HPV® SCR (index assay) identifies HPV‐16 and HPV‐18 separately, 11 other hrHPV in aggregate and includes quality controls for sample adequacy, DNA extraction efficiency and PCR inhibition. 1300 VALGENT‐2 study samples (from women aged 20–60 attending the Scottish cervical cancer screening program) were tested with the index assay and the GP5+/6+ PCR enzyme immunoassay (standard comparator assay). Non‐inferior accuracy detecting cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) of the index versus comparator was verified. Intra‐ and interlaboratory reproducibility of the index was evaluated by overall concordance and Cohen's kappa, using a sub‐population ( n = 526). Relative sensitivity and specificity for CIN2+ of the index versus comparator were 1.01 (95% confidence interval [CI]: 0.99–1.03) and 1.02 (95% CI: 1.0–1.04), respectively. Noninferiority p values were all ≤0.05, except for CIN3+ in patients ≥30 years. Excellent intra‐ and interlaboratory reproducibility was shown with concordance >98% and kappas >0.95. OncoPredict HPV® SCR fulfills the three international validation criteria for hrHPV DNA tests in cervical cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsUterine Cervical DysplasiaHumansFemaleHuman Papillomavirus VirusesGenotyping TechniquesEarly Detection of CancerReproducibility of ResultsPapillomaviridaeSensitivity and SpecificityReal-Time Polymerase Chain Reaction

Stichwörter der Autor:innen

HPV genotypingOncoPredict HPV®VALGENTcervical cancerhuman papillomavirustest validation

Autor:innen und Institutionen

  • Unit of Cancer Epidemiology/Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.
  • Laboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK.
  • HPV Research Group, Centre for Reproductive Health, University of Edinburgh, Edinburgh, Scotland, UK.
  • Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.

ORCID-Profile: Clementina E Cocuzza, Ramya Bhatia

Förderung

  • European Commission

Zitieren

APA

Dhillon, S. K., Cocuzza, C. E., Chung, P. Y. J., Martinelli, M., Giubbi, C., Njoku, R. C., Bhatia, R., Cuschieri, K., & Arbyn, M. (2023). Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework. Journal of Medical Virology. https://doi.org/10.1002/jmv.28417

Vancouver

Dhillon SK, Cocuzza CE, Chung PYJ, Martinelli M, Giubbi C, Njoku RC, et al. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework. Journal of Medical Virology. 2023. doi:10.1002/jmv.28417

BibTeX
@article{Dhillon2023,
  author = {Dhillon, Sharonjit K and Cocuzza, Clementina E and Chung, Pui Yan Jenny and Martinelli, Marianna and Giubbi, Chiara and Njoku, Ruth C and Bhatia, Ramya and Cuschieri, Kate and Arbyn, Marc},
  title = {Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28417}
}
Kostenlos starten →